Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
IPO Year:
Exchange: NASDAQ
Website: apyxmedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/17/2024 | Neutral | BTIG Research | |
| 7/14/2023 | $8.00 | Overweight | Stephens |
| 5/20/2022 | $12.00 | Buy | Lake Street |
| 8/13/2021 | $12.00 → $14.00 | Market Outperform | JMP Securities |
Highlighting Real Patient Journeys and Empowering Confidence Through Loose Skin Solutions and Body Contouring CLEARWATER, Fla., May 30, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of the proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, is once again taking center stage—this time at Miami Swim Week. Following the success of its groundbreaking debut at New York Fashion Week, Renuvion will proudly feature real patients on the runway, celebrating the power of transformation and self-confidence.
The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the "FDA") for the AYON Body Contouring System™ ("AYON"). The Company is actively pr
Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March
Two studies report favorable clinical outcomes and safety data for Renuvion® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin CLEARWATER, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform marketed and sold as Renuvion®, today announced the publication of two peer-reviewed clinical studies evaluating the use of Renuvion during body contouring procedures that also included lipoabdominopla
CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Partic
Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin CLEARWATER, Fla., March 25, 2025 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, announced today that Renuvion has been named this year's NewBeauty Award winner in the "Best Minimally Invasive Skin Tightener"1 category. The NewBeauty Awards franchise is a leading and trusted program in the beauty space. The award winners represent effective solutions to consumers' biggest beauty in
The number of single-use handpiece units shipped in Q4 2024 exceeded expectations, increasing 5% overall and 20% in the U.S. compared to the same period last yearSubmitted a 510(k) premarket notification to the U.S. FDA for the AYON™ Body Contouring System ahead of schedule and preparing for a planned launch in the back half of 2025, pending clearanceManagement to host a conference call today at 8:30 a.m. ET CLEARWATER, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial
CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th. Management will host a conference call at 8:30 a.m. Eastern Time on Thursday, March 13th to discuss the results of the fourth quarter and fiscal year 2024, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international call
CLEARWATER, Fla, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Revenue Summary: Total revenue expected to be in a range of approximately $14.1 to $14.3 million, representing a decrease of 4% to 3% year-over-year. Advanced Energy revenue expected to be in a range of approximately $12.0 to $12.2 million, which is relatively flat year-over-year.OEM revenue expected to be approximately $2.1 million, repres
CLEARWATER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (the "FDA") for the AYON Body Contouring System. The AYON Body Contouring System was developed with a focus on versatility and innovation. AYON has been designed to be the only device a surgeon needs for comprehensive body contouring solutions. This all-in-one system integrates advanced modalities to perform multiple functions seamlessly, removing
SC 13G - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13D/A - Apyx Medical Corp (0000719135) (Subject)
SC 13D - Apyx Medical Corp (0000719135) (Subject)
SC 13D - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SD - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
10-Q - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
10-K - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4/A - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4/A - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
BTIG Research initiated coverage of Apyx Medical with a rating of Neutral
Stephens initiated coverage of Apyx Medical with a rating of Overweight and set a new price target of $8.00
Lake Street initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $12.00
JMP Securities reiterated coverage of Apyx Medical with a rating of Market Outperform and set a new price target of $14.00 from $12.00 previously
Piper Sandler reiterated coverage of Apyx Medical with a rating of Overweight and set a new price target of $12.00 from $8.00 previously
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that the Company has appointed Wendy Levine to the Board of Directors, effective August 25, 2021. Ms. Levine will serve as a Director and member of the Regulatory Compliance Committee. "I am pleased to welcome Ms. Levine to our Board and look forward to leveraging her 25 years of healthcare marketing and advertising experience across the pharmaceutical, biotech, medical device and vaccine sectors," said Charlie Goodwin, Chief
Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March
CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Partic
CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th. Management will host a conference call at 8:30 a.m. Eastern Time on Thursday, March 13th to discuss the results of the fourth quarter and fiscal year 2024, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international call
CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th. Management will host a conference call at 8:00 a.m. Eastern Time on November 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international callers) and provide access code 13
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2024; and updated its financial expectations for the full year ending December 31, 2024. Second Quarter 2024 Financial Summary: Total revenue of $12.1 million, a decrease of 10% year-over-year. Advanced Energy revenue of $9.8 million, a decrease of 17% year-over-year. OEM revenue of $2.4 million, an increase of 29% year-over-year. Net loss attributable to stockholders of $6.6 million, an increase of $5.6 million, or 5
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the second quarter of fiscal year 2024 will be released after the market closes on Thursday, August 8th. Management will host a conference call at 5:00 p.m. Eastern Time on August 8th to discuss the results of the quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 888-645-4404 (or 862-298-0702 for international callers) and provide access code 13747529. Participants should ask for the Apyx Medical Corporation Call.
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024. First Quarter 2024 Financial Summary: Total revenue of $10.2 million, a decrease of 16% year-over-year. Advanced Energy revenue of $7.5 million, a decrease of 23% year-over-year. OEM revenue of $2.8 million, an increase of 14% year-over-year. Net loss attributable to stockholders of $7.6 million, an increase of $4.1 million, or 118%, ye
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th. Management will host a conference call at 8:00 a.m. Eastern Time on May 9th to discuss the results of the quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 888-645-4404 (or 862-298-0702 for international callers) and provide access code 13745889. Participants should ask for the Apyx Medical Corporation Call. A live webcast
Advanced Energy Sales increased 15% year-over-year and 23% quarter-over-quarter in the fourth quarter; increased 18% year-over-year in 2023 Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter and full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024. Fourth Quarter 2023 Financial Summary: Total revenue of $14.7 million, an increase of 16% year-over-year. Advanced Energy revenue of $12.1 million, an increase of 15% year-over-year. OEM r
Apyx® Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st. Management will host a conference call at 8:00 a.m. Eastern Time on March 21st to discuss the results of the quarter and year, and to host a question and answer session. To listen to the call by phone, interested parties may dial 877-407-8289 (or 201-689-8341 for international callers) and provide access code 13744178. Participants should ask for the Apyx Medical Corporation Cal